David F McDermott Selected Research

aldesleukin (Proleukin)

5/2017	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
2/2015	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
8/2009	The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David F McDermott Research Topics

Disease

129	Renal Cell Carcinoma (Grawitz Tumor) 02/2022 - 07/2003
97	Neoplasms (Cancer) 02/2022 - 01/2005
44	Melanoma (Melanoma, Malignant) 01/2022 - 10/2002
18	Kidney Neoplasms (Kidney Cancer) 01/2022 - 04/2004
12	Fatigue 01/2020 - 07/2003
11	Disease Progression 01/2021 - 01/2010
8	Neoplasm Metastasis (Metastasis) 10/2018 - 01/2005
7	Hypertension (High Blood Pressure) 01/2020 - 03/2010
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2019 - 06/2012
4	Hypoxia (Hypoxemia) 01/2022 - 07/2015
4	Body Weight (Weight, Body) 04/2018 - 08/2010
4	Anemia 11/2015 - 07/2003
3	Inflammation (Inflammations) 01/2022 - 01/2020
3	Exanthema (Rash) 01/2021 - 03/2010
3	Colitis 11/2016 - 04/2015
2	Tics (Tic) 01/2021 - 01/2019
2	Stomatitis 01/2020 - 09/2007
2	Carcinoma (Carcinomatosis) 01/2020 - 09/2005
2	Pruritus (Itching) 01/2020 - 08/2016
2	Pneumonia (Pneumonitis) 01/2019 - 12/2016
2	Cardiotoxicity 10/2018 - 02/2009
2	Brain Neoplasms (Brain Tumor) 03/2010 - 12/2009
2	Nausea 09/2007 - 07/2003
2	Vomiting 09/2007 - 07/2003
1	Autoimmune Hepatitis 01/2021
1	Carcinogenesis 01/2021
1	Chronic Renal Insufficiency 01/2021

Drug/Important Bio-Agent (IBA)

39	NivolumabIBA 01/2022 - 07/2013
30	Interleukin-2 (IL2)IBA 01/2019 - 10/2002
29	Immune Checkpoint InhibitorsIBA 02/2022 - 07/2013
26	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 02/2009
26	Sunitinib (Sutent)FDA Link 02/2022 - 10/2011
26	IpilimumabIBA 01/2022 - 08/2010
22	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2009
19	Bevacizumab (Avastin)FDA Link 02/2022 - 03/2010
16	atezolizumabIBA 02/2022 - 11/2014
12	B7-H1 AntigenIBA 01/2022 - 07/2013
10	Sorafenib (BAY 43-9006)FDA Link 10/2021 - 05/2008
10	Everolimus FDA Link 01/2021 - 08/2013
9	Pharmaceutical PreparationsIBA 01/2022 - 03/2010
9	CytokinesIBA 10/2019 - 04/2004
8	pembrolizumabIBA 10/2021 - 04/2015
7	LigandsIBA 02/2022 - 06/2012
7	TOR Serine-Threonine KinasesIBA 08/2016 - 09/2007
6	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 07/2015
6	Monoclonal AntibodiesIBA 11/2021 - 07/2013
6	InterferonsIBA 06/2014 - 01/2005
4	tivozanibIBA 01/2022 - 01/2020
4	pazopanib FDA Link 10/2021 - 12/2017
4	Axitinib (AG 013736)IBA 01/2021 - 01/2018
4	CTLA-4 AntigenIBA 01/2020 - 08/2010
4	Tyrosine Kinase InhibitorsIBA 01/2020 - 05/2006
4	MTOR InhibitorsIBA 01/2018 - 08/2010
3	Proteins (Proteins, Gene)FDA Link 11/2021 - 01/2016
3	Biological ProductsIBA 01/2021 - 10/2016
3	Lipase (Acid Lipase)FDA Link 01/2021 - 08/2016
3	Alanine Transaminase (SGPT)IBA 10/2019 - 11/2016
3	AntibodiesIBA 05/2017 - 03/2014
3	aldesleukin (Proleukin)FDA Link 05/2017 - 08/2009
3	Phosphotransferases (Kinase)IBA 08/2016 - 05/2006
3	temsirolimus FDA Link 01/2016 - 09/2007
3	Dacarbazine (DIC)FDA LinkGeneric 04/2015 - 10/2002
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2022 - 01/2022
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 10/2016
2	belzutifanIBA 10/2021 - 01/2021
2	RNA (Ribonucleic Acid)IBA 10/2021 - 01/2020
2	Interleukin-8 (Interleukin 8)IBA 03/2021 - 01/2020
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 11/2010
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2018
2	Amylases FDA Link 10/2019 - 08/2016
2	Programmed Cell Death 1 ReceptorIBA 01/2019 - 07/2018
2	Sirolimus (Rapamycin)FDA Link 10/2018 - 01/2018
2	raf KinasesIBA 08/2017 - 07/2015
2	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 01/2013
2	Gemcitabine FDA Link 10/2015 - 10/2011
2	Immunoglobulins (Immunoglobulin)IBA 06/2015 - 06/2015
2	VemurafenibIBA 06/2014 - 07/2013
2	Carboplatin (JM8)FDA LinkGeneric 01/2012 - 01/2009
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2012 - 01/2009
2	Hemoglobins (Hemoglobin)IBA 11/2011 - 12/2009
2	CalciumIBA 01/2011 - 12/2009
2	Temozolomide (Temodar)FDA LinkGeneric 12/2009 - 10/2002
2	Interferon-alpha (Interferon Alfa)IBA 01/2009 - 09/2007
2	Interferon-gamma (Interferon, gamma)IBA 10/2007 - 07/2003
1	Small Nucleolar RNA (snoRNA)IBA 02/2022
1	Polytetrafluoroethylene (Teflon)FDA Link 01/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	AndrogensIBA 01/2022
1	tremelimumabIBA 11/2021
1	Angiopoietin-2IBA 11/2021
1	MEDI3617IBA 11/2021
1	Immunoglobulin G (IgG)IBA 11/2021
1	Alanine (L-Alanine)FDA Link 01/2021
1	Chemokine ReceptorsIBA 01/2021
1	mavorixaforIBA 01/2021

Therapy/Procedure

85	Therapeutics 01/2022 - 01/2005
31	Immunotherapy 01/2022 - 01/2007
6	Nephrectomy 02/2015 - 10/2007
4	Aftercare (After-Treatment) 01/2022 - 04/2014
3	Drug Therapy (Chemotherapy) 01/2017 - 05/2008